Skip to main content

Table 4 Serum metabolite profiles of MG patients before and after QJF treatment

From: Serum proteomic, peptidomic and metabolomic profiles in myasthenia gravis patients during treatment with Qiangji Jianli Fang

Metabolite Formula ± ppma Peak area (Mean ± SDb) % Changec P valued
Before therapy After therapy
γ-aminobutyric acid C4H9NO2 −71.7 10.2 ± 0.52 15.80 ± 0.81 54.9 0.000
Coenzyme Q4 C29H42O4 43.1 12.28 ± 3.41 7.89 ± 0.89 −35.7 0.000
Taurallocholic acid C26H45NO7S −75.8 0.03 ± 0.17 6.72 ± 5.32 19016.7 0.000
Dipalmitoylphosphatidic acid C35H69O8P 92.9 0.19 ± 0.38 6.65 ± 2.35 3397.8 0.000
Phytosphingosine C18H39NO3 −2.3 1.73 ± 1.53 19.11 ± 7.29 1004.8 0.000
5b-Cyprinolsulfate C27H48O8S −50.2 0.38 ± 0.61 2.63 ± 2.01 591.9 0.000
Thromboxane B2 C20H34O6 40 1.13 ± 1.45 2.92 ± 1.91 158.3 0.000
Biliverdin IX C33H34N4O6 3.6 22.71 ± 5.78 6.36 ± 3.54 −71.9 0.000
  1. aMass differences between the calculated and measured metabolite masses.
  2. bMean peak areas of metabolites in patients before and after QJF treatment. SD denotes standard deviation.
  3. cChanges are calculated as the difference in the median concentrations before and after QJF treatment.
  4. dP values were calculated by Student’s t-test.